Amgen Inc. (AMGN)
After hours:
| Previous Close | 314.72 |
| Open | 315.00 |
| Bid | 312.44 x 100 |
| Ask | 312.62 x 100 |
| Day's Range | 310.38 - 315.28 |
| 52 Week Range | 211.71 - 329.72 |
| Volume | |
| Avg. Volume | 2,771,277 |
| Market Cap | 167.62B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | 44.64 |
| EPS (TTM) | 7.00 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | 9.00 (2.88%) |
| Ex-Dividend Date | May 16, 2024 |
| 1y Target Est | 316.85 |
ZacksAmgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
PR NewswireFDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA has received accelerated approval based on the encouraging response rate and duration of response (DoR) observed in clinical studies. Continued approval for this indication may be contingent upon verificatio
